ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Bypass Budget Is Realistic, Defensible Plan, Broder Says

September 27, 1991

Final Issue Of 1988

December 9, 1988

IOM Report Lists Cancer CER Priorities

July 3, 2009

Translplants Not Best Choice in Subset of ALL Patients

April 27, 2012

In Brief: Chabner Names DCT Acting Director, Schepartz Returns To Deputy Job; GM Winners Announced

July 3, 1981

NINDS Awards Grants For Brain Tumor Centers

December 11, 1992